ArticleOncotarget2024
From osimertinib to preemptive combinations.
Mikhail V BlagosklonnyPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleOncotarget2024
Mikhail V BlagosklonnyPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.